Clinical relevance of DPYD variants c. 1679T> G, c. 1236G> A/HapB3, and c. 1601G> A as predictors of severe fluoropyrimidine-associated toxicity: a systematic …
D Meulendijks, LM Henricks, GS Sonke… - The Lancet …, 2015 - thelancet.com
Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity
U Amstutz, TK Froehlich, CR Largiadèr - Pharmacogenomics, 2011 - Taylor & Francis
The importance of polymorphisms in the dihydropyrimidine dehydrogenase (DPD) gene
(DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU) based chemotherapy has …
(DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU) based chemotherapy has …
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update
U Amstutz, LM Henricks, SM Offer… - Clinical …, 2018 - Wiley Online Library
The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …
Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity
SM Offer, CC Fossum, NJ Wegner, AJ Stuflesser… - Cancer research, 2014 - AACR
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of the uracil
catabolic pathway, being critically important for inactivation of the commonly prescribed anti …
catabolic pathway, being critically important for inactivation of the commonly prescribed anti …
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
MJ Deenen, J Tol, AM Burylo, VD Doodeman… - Clinical Cancer …, 2011 - AACR
Purpose: To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide
polymorphisms (SNP) and haplotypes on outcome of capecitabine. Experimental Design …
polymorphisms (SNP) and haplotypes on outcome of capecitabine. Experimental Design …
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
A Loganayagam, M Arenas Hernandez… - British journal of …, 2013 - nature.com
Background: Fluoropyrimidine drugs are extensively used for the treatment of solid cancers.
However, adverse drug reactions are a major clinical problem, often necessitating treatment …
However, adverse drug reactions are a major clinical problem, often necessitating treatment …
[HTML][HTML] Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
M Panczyk - World Journal of Gastroenterology: WJG, 2014 - ncbi.nlm.nih.gov
During the past two decades the first sequencing of the human genome was performed
showing its high degree of inter-individual differentiation, as a result of large international …
showing its high degree of inter-individual differentiation, as a result of large international …
DPYD IVS14+1G>A and 2846A>T Genotyping for the Prediction of Severe Fluoropyrimidine-Related Toxicity: A Meta-Analysis
Aim: In the present study we conducted a systematic review and meta-analysis of published
data to quantify the impact of the DPYD IVS14+ 1G> A and 2846A> T variants on the risk of …
data to quantify the impact of the DPYD IVS14+ 1G> A and 2846A> T variants on the risk of …
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity
TK Froehlich, U Amstutz, S Aebi… - … journal of cancer, 2015 - Wiley Online Library
We investigated the clinical relevance of dihydropyrimidine dehydrogenase gene (DPYD)
variants to predict severe early‐onset fluoropyrimidine (FP) toxicity, in particular of a recently …
variants to predict severe early‐onset fluoropyrimidine (FP) toxicity, in particular of a recently …